VVZ API is not affiliated with ETH Zurich. Data might be outdated or incorrect. Please view the official ETHZ Vorlesungsverzeichnis for binding information.
Abstract
The course covers the key concepts and strategic frameworks used in the late-stage development and commercialization of medicines, including Go-To-Market (commercial, medical and patient affairs) strategy, asset and portfolio management and other related topics.
Objective
- Participants have a high-level understanding of the key strategic questions and decision points along the lifecycle of a drug: from research to commercialization, enabling them to understand how biopharmaceutical companies connect the dots between the different disciplines/ functions to bring medicines to patients. - Students understand the Go-To-Market strategy in the pharmaceutical companies. They have detailed insights into the functions involved (incl. Medical Affairs, Patient Affairs, Sales and Marketing) and understand where collaboration/ interdependencies among those functions is required. - Participants have a deeper understanding of the asset and portfolio strategy in the biopharmaceutical industry. They are able to explain how a company can strengthen their internal portfolio with external business development opportunities (incl. partnerships, licensing, mergers & acquisitions). - Students are able to discuss case studies and tackle real-life examples of how companies executed on some of those strategies. They will place a special focus on the interconnection of functions, and decision making along the pharmaceutical product value chain.
Content
- Pharmaceutical product lifecycle, value inflection points along the product development and commercialization, success KPIs in the development of medicines - The role of medical affairs, patient affairs, sales and marketing functions; the mandates these functions have and the methodologies they use to bring medicines to patients - Methodologies for asset valuation and portfolio management in the biopharmaceutical company, qualitative and quantitative considerations on business development / mergers & acquisitions - Use cases / examples of the pharmaceutical industry showcasing some of the learnings